Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors

@article{Jiang2019GenomewideAO,
  title={Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors},
  author={T Jiang and Bojun Wei and D. X. Zhang and L. Li and Guoliang Qiao and Xingwei Yao and Z W Chen and X. Liu and X Y Du},
  journal={Osteoporosis International},
  year={2019},
  pages={1-9}
}
  • T. Jiang, B. Wei, X. Du
  • Published 10 April 2019
  • Medicine, Biology
  • Osteoporosis International
SummaryDiagnosis of parathyroid carcinoma on histological examination is challenging. Thousands of differentially expressed lncRNAs were identified on the microarray data between parathyroid cancer and adenoma samples. Four lncRNAs were significantly dysregulated in further validation. The “lncRNA score” calculated from these lncRNAs differentiated parathyroid carcinomas from adenomas. LncRNAs serve as biomarkers for parathyroid cancer diagnosis.IntroductionDiagnosis of parathyroid carcinoma… 
View on Springer
ncbi.nlm.nih.gov
7 Citations
Background Citations
1
Methods Citations
1
Results Citations
2

7 Citations

The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
TLDR
The preliminary data evaluating whether BC200 could be an accurate non-invasive biomarker of PCas to support the clinical management of patients affected by parathyroid tumors at diagnosis, prognosis and follow-up are extended.
The Oncosuppressors MEN1 and CDC73 Are Involved in lncRNA Deregulation in Human Parathyroid Tumors
  • A. Morotti, I. Forno, V. Vaira
  • Biology, Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2020
TLDR
Light is shed on deregulation of lncRNAs in human parathyroid tumors and circuits between lnc RNAs and the oncosuppressors MEN1 or CDC73 may have a role inParathyroid tumorigenesis as epigenetic modulators.
Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?
TLDR
Insight is given into the ncRNAs involved in parathyroid tumorigenesis, which could be used in the future either as innovative diagnostic biomarkers or as therapeutic targets for the treatment of this endocrine neoplasia.
Parathyroid cancer: A systematic review of diagnostic biomarkers.
Role of LncRNA score and PVT1 in primary hyperparathyroidism-- a preliminary study
TLDR
Increased lncRNA score is correlated with an elevated level of serum calcium, which may serve as a potential biomarker for PC diagnosis, especially with hypercalcemia.
Intratumor heterogeneity in human parathyroid tumors.
TLDR
Heterogeneity is likely involved in the phenotypic variability of the parathyroid tumors, and it should be considered in the clinical management, though at present target therapies are not available, with the exception of the calcium sensing receptor agonists.
Parathyroid Carcinoma and Ectopic Secretion of Parathyroid hormone.

References

SHOWING 1-10 OF 34 REFERENCES
Plasma lncRNA GAS8-AS1 as a Potential Biomarker of Papillary Thyroid Carcinoma in Chinese Patients
Background Long noncoding RNAs (lncRNAs) were recently shown to have potential in the diagnosis and prognosis for numerous cancers. lncRNA GAS8-AS1 is decreased in papillary thyroid cancer (PTC)…
Long noncoding RNAs: emerging players in thyroid cancer pathogenesis.
TLDR
The tumor-suppressive and oncogenic roles of various lncRNAs and their possible disease associations implicated in thyroid carcinogenesis are discussed extensively.
Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis
TLDR
The specificity of parafibromin staining was satisfactory for diagnosis of PTCA, while the sensitivity was limited and it was suggested that a standardized IHC protocol and scoring system criteria should be applied in future studies to improve the diagnostic performance of parfibrom in staining.
Role of the lncRNA-p53 regulatory network in cancer.
TLDR
How lncRNAs serve as p53 regulators or p53 effectors is discussed, which may prove to be valuable biomarkers for cancer diagnosis or potential targets for cancer therapy.
Oncogenic MicroRNA-155 Down-regulates Tumor Suppressor CDC73 and Promotes Oral Squamous Cell Carcinoma Cell Proliferation
Background: Cause of the complete loss of CDC73 in a subset of parathyroid tumors remains to be elucidated in the absence of a second mutation and promoter methylation. Results: Oncogenic miR-155…
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
TLDR
Results suggest that positive staining for PGP9.5 has utility as a marker for parathyroid malignancy, with a slightly superior sensitivity and similar high specificity to that of parafibromin.
Parafibromin, Galectin-3, PGP9.5, Ki67, and Cyclin D1: Using an Immunohistochemical Panel to Aid in the Diagnosis of Parathyroid Cancer
TLDR
A panel of immunohistochemistry (PGP9.5, galectin-3, parafibromin, and Ki67) is better than any single marker and can be used to supplement classical histopathology in diagnosing parathyroid cancer.
Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
TLDR
It is shown that negative parafibromin staining is almost invariably associated with HRPT2 mutations and confirmed that loss of parfibrom in staining strongly predicts parathyroid malignancy.
Diagnosis and management of parathyroid cancer
TLDR
A validated, histopathology-based prognostic classification can identify patients in need of close follow-up and adjuvant therapy, and should prove valuable to stratify clinical trial cohorts: low-risk patients rarely die from parathyroid cancer, even on long-term follow- up, whereas 5-year mortality in high- risk patients is around 50%.
Long non-coding RNAs as regulators of the endocrine system
TLDR
The associations of lncRNAs with nuclear receptors involved in major hormonal signalling pathways, such as estrogen and androgen receptors, and the relevance of these associations in certain endocrine cancers are addressed.
...
...